Expression and clinical significance of RhoC and RhoGDIa in non-small cell lung cancer

Chinese Journal of Lung Cancer

Volumn 11, Issue 3, 2008, Pages 391-397

  Han, Yuchen ^a   Wu, Yanni ^b   Gao, Shuang ^c   Xu, Yuexin ^a   Guan, Zhongyan ^a   Qiu, Xueshan ^a   Wang, Enhua ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b XUZHOU MEDICAL UNIVERSITY   (China)

^c SHANGHAI CHEST HOSPITAL   (China)

Author keywords

Lung neoplasms; Metastasis; Prognosis; RhoC; RhoCDIa

Indexed keywords

BETA ACTIN; GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR; MESSENGER RNA; PROTEIN RHOC; PROTEIN RHOGDIALPHA; REGULATOR PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GIANT CELL CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; SURVIVAL TIME;

EID: 47149117426     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2008.03.007     Document Type: Article

References (27)

1. Sandrine, Manneville E, Hall A, et al. RhoGTPases in cell biology. Nature, 2002, 420(12): 629-635.
2. Hakem A, Sanchez-Sweatman O, You-Ten A, et al. RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes Dev, 2005, 19(17): 1974-1979.
3. Clark EA, Golub TR, Lander ES, et al. Genomic analysis of metastasis reveals an essential role for RhoC. Nature, 2000, 406 (6795): 532-535.
4. Ridley A. Molecular switches in metastasis. Nature, 2000, 406 (6795): 466-467.
5. Fukumoto Y, Kaibuchi K, Hori Y, et al. Molecular cloning and characterization of a novel type of regulatory protein (GDI) for the rho proteins, ras p21-like small GTP-binding proteins. Oncogene, 1990, 5 (9): 1321-1328.
6. DerMardirossian C, Bokoch GM. GDIs: central regulatory molecules in Rho GTPase activation. Trends Cell Biol, 2005, 15(7): 356-363.
7. Dransart E, Olofsson B, Cherfils J. RhoGDIs revisited: novel roles in Rho regulation. Traffic, 2005, 6(11): 957-966.
8. Berman DM, Shih I, Burke LA, et al. Profiling the activity of G proteins in patient-derived tissues by rapid affinity-capture of signal transduction paoteins (GRASP). Proteomics, 2004, 4(3): 812-818.
9. Jones MB, Krutzsch H, Shu H, et al. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics, 2002, 2(1): 76-84.
10. Chumbalkar VC, Subhashini C, Dhople VM, et al. Differential protein expression in human gliomas and molecular insights. Proteomics, 2005, 5(4): 1167-1177.
11. Jiang WG, Watkins G, Lane J, et al. Prognostic value of rho GTPases and rho guanine nucleotide dissociation inhibitors in human breast cancers. Clin Cancer Res, 2003, 9(17): 6432-6440.
12. Fritz G, Brachetti C, Bahlmann F, et al. Rho GTPases in human breast tumors: expression and mutation analysis and correlation with clinical parameters. Br J Cancer, 2002, 87(6): 635-644.
13. Blackhall FH, Wigle DA, Jurisica I, et al. Validating the prognostic value of marker genes derived from a non-small cell lung cancer microarray study. Lung Cancer, 2004, 46(2): 197-204.
14. Wang W, Yang LY, Yang ZL, et al. Elevated expression of autocrine motility factor receptor correlates with overexpression of RhoC and indicates poor prognosis in hepatocellular carcinoma. Dig Dis Sci, 2007, 52(3): 770-775.
15. Kleer CG, Teknos TN, Islam M, et al. RhoC GTPase expression as a potential marker of lymph node metastasis in squamous cell carcinomas of the head and neck. Clin Cancer Res, 2006, 12(15): 4485-4490.
16. Bellovin DI, Simpson KJ, Danilov T, et al. Reciprocal regulation of RhoA and RhoC characterizes the EMT and identifies RhoC as a prognostic marker of colon carcinoma. Oncogene, 2006, 25(52): 6959-6967.
17. Simpson KJ, Dugan AS, Mercurio AM. Functional analysis of the contribulion of RhoA and RhoC GTPases to invasive breast carcinoma. Cancer Res, 2004, 64(23): 8694-8701.
18. Pan Y, Bi F, Liu N, et al. Expression of seven main Rho family members in gastric carcinoma. Biochem Biophys Res Commun, 2004, 315(3): 686-691.
19. Pille JY, Denoyelle C, Varet J, et al. Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. Mol Ther, 2005, 11(2): 267-274.
20. Shikada Y, Yoshino I, Okamoto T, et al. Higher expression of RhoC is related to invasiveness in non-small cell lung carcinoma. Clin Cancer Res, 2003, 9(14): 5282-5286.
21. Bokoch GM, Bohl BP, Chuang TH. Guanine nucleotide exchange regulates membrane translocation of Rac/Rho GTP-binding proteins. J Biol Chem, 1994, 269(50): 31674-31679.
22. Olofsson B. Rho guanine dissociation inhibitors: pivotal molecules in cellular signalling. Cell Signal, 1999, 11(8): 545-554.
23. MacKeigan JP, Clemants CM, Lich JD, et al. Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: identification of RS/DJ-1 and RhoGDIa. Cancer Res, 2003, 63(20): 6928-6934.
24. Zhang B. Rho GDP dissociation inhibitors as potential targets fro anticancer treatment. Drug Resustance Updates, 2006, 9(3): 134-141.
25. Dovas A, Couchman JR. RhoGDI: multiple functions in the regulation of Rho family GTPase activities. Biochem J, 2005, 390(Pt 1): 1-9.
26. Zhang B, Zhang Y, Shacter E. Caspase 3-Mediated inactivation of Rac GTPases Promotes drug-induced apoptosis in human lymphoma. Mol Cell Biol, 2003, 23(16): 5716-5725.
27. Zhang B, Zhang Y, Dagher MC, et al. Rho GDP dissociation inhibitor protects cancer cells against drug-induced apoptosis. Cancer Res, 2005, 65(14): 6054-6062.